CAS: 130466-38-5 - Methanesulfonamide, N-[2-[(2R,12bS)-1,3,4,6,7,12b-hexahydro-2′-oxospiro[2H-benzofuro[2,3-a]quinolizine-2,4′-imidazolidin]-3′-yl]ethyl]-, hydrochloride (1:1)
Formula:C20H26N4O4S·ClH
InChI:InChI=1S/C20H26N4O4S.ClH/c1-29(26,27)22-8-11-24-19(25)21-13-20(24)7-10-23-9-6-15-14-4-2-3-5-17(14)28-18(15)16(23)12-20;/h2-5,16,22H,6-13H2,1H3,(H,21,25);1H/t16-,20+;/m0./s1
InChI key:InChIKey=UTMOWVIYZQWJHT-VASSOYJASA-N
SMILES:Cl.O=C1NCC2(N1CCNS(=O)(=O)C)CCN3CCC=4C=5C=CC=CC5OC4C3C2
- Synonyms:
- Spiro[2H-benzofuro[2,3-a]quinolizine-2,4′-imidazolidine], methanesulfonamide deriv.
- MK 467
- Methanesulfonamide, N-[2-[(2R,12bS)-1,3,4,6,7,12b-hexahydro-2′-oxospiro[2H-benzofuro[2,3-a]quinolizine-2,4′-imidazolidin]-3′-yl]ethyl]-, monohydrochloride
- Methanesulfonamide, N-[2-[(2R,12bS)-1,3,4,6,7,12b-hexahydro-2′-oxospiro[2H-benzofuro[2,3-a]quinolizine-2,4′-imidazolidin]-3′-yl]ethyl]-, hydrochloride (1:1)
- Methanesulfonamide, N-[2-(1,3,4,6,7,12b-hexahydro-2′-oxospiro[2H-benzofuro[2,3-a]quinolizine-2,4′-imidazolidin]-3′-yl)ethyl]-, monohydrochloride, (2R-trans)-
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
Vatinoxan hydrochloride REF: 3D-FFA46638CAS: 130466-38-5 | Min. 95% | To inquire | Tue 18 Feb 25 | |
Vatinoxan hydrochloride REF: TM-T13285CAS: 130466-38-5 | 98% | 738.00 €~3,458.00 € | Tue 11 Mar 25 |
Vatinoxan hydrochloride
CAS:130466-38-5
Vatinoxan hydrochloride is a drug that belongs to the class of α2-adrenergic receptor antagonists. It …
Formula:
C20H27ClN4O4S
Purity:
Min. 95%
Molecular weight:
455 g/mol
Ref: 3D-FFA46638
5mg | To inquire | ||
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025
Vatinoxan hydrochloride
CAS:130466-38-5
Vatinoxan hydrochloride is an antagonist of the peripheral α2 adrenergic receptors.
Formula:
C20H27ClN4O4S
Purity:
98%
Color and Shape:
Solid
Molecular weight:
454.97
Ref: TM-T13285
25mg | 1,967.00 € | ||
50mg | 2,598.00 € | ||
100mg | 3,458.00 € |
Estimated delivery in United States, on Tuesday 11 Mar 2025